Research in the department of Molecular Biology and Biotechnology has led to the setting up of three spinout companies. Unusually, all three are still operating!
Departmental expertise in the production of antibodies led to the spinout of Bioserv as an independent company specialising in the production and processing of biomolecules, mainly antibodies. The company was initially housed in space within the department but has now moved out to external premises.
Asterion grew out of a collaboration between Molecular Biology and Biotechnology and the Medical School at Sheffield, to develop new technologies for third generation drugs that would last longer in the human body, with fewer side effects. Current products treat growth disorders, anaemia and neutropenia.
Our expertise in microbiology led to Absynth, which develops vaccines and antibodies to prevent and treat bacterial infections. Its main target is Staphylococcus aureus, including its more problematic drug-resistant form, methicillin-resistant S. aureus (MRSA), the worrying hospital superbug.